Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD. Ross Camidge, Shun Lü, Fedor Moiseenko et al.|Journal of Clinical Oncology|2024Cited by 131
MA07.07 Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLCBenjamin Besse, E. Felip, P. Tomasini et al.|Journal of Thoracic Oncology|2025Cited by 1